Three Key Takeaways
- FermaHop Pro+ delivers broad-spectrum suppression of Gram-positive bacterial contaminants across the full pH range encountered in commercial dry-mill ethanol fermentation.
- Commercial field evaluations demonstrated maintained ethanol yield performance, controlled lactic acid accumulation, and average savings of $51 per fermentation relative to incumbent antimicrobial programs.
- Eliminate antibiotic residues from DDGS, safeguarding feed quality amid rising global regulations.
Bacterial contamination remains one of the most significant operational constraints in commercial dry-mill ethanol production. Gram-positive lactic acid bacteria (LAB), particularly Lactobacillus and Pediococcus species, compete directly with Saccharomyces cerevisiae for fermentable carbohydrates while producing inhibitory metabolites including lactic acid, acetic acid, and exopolysaccharides.
As bacterial load increases, ethanol facilities commonly observe reduced yeast viability, slower fermentation kinetics, elevated residual sugars, increased glycerol production, and lower starch-to-ethanol conversion efficiency. These process disruptions become increasingly difficult to manage under variable fermentation conditions common in ethanol operations.
Limitations of Conventional Antibiotic Programs
Antibiotics such as virginiamycin have historically served as primary bacterial-control tools in fuel ethanol production. These compounds function through highly specific biochemical inhibition mechanisms, including interference with bacterial protein synthesis.
While effective under controlled conditions, prolonged exposure under fluctuating fermentation environments can increase selective pressure on microbial populations and contribute to reduced susceptibility over time. Additional concerns include narrower effective pH ranges, DDGS residue considerations, increased regulatory scrutiny, and multi-chemistry inventory management.
FermaHop Pro+: Broad-Spectrum Hop-Acid Technology
FermaHop Pro+ was developed specifically for broad-spectrum bacterial suppression across the full pH range encountered in commercial dry-mill ethanol fermentation, approximately pH 4.0 to 5.8.
The proprietary hop-acid formulation targets Gram-positive contaminants including Lactobacillus spp., Pediococcus spp., and other spoilage-associated LAB populations. Unlike antibiotics, which inhibit discrete intracellular pathways, hop acids act by dissipating the transmembrane pH gradient required for nutrient transport and cellular energy metabolism
Mechanism of Action
The antimicrobial activity of hop acids is associated primarily with the undissociated form of the molecule. As extracellular pH decreases, hop acids become increasingly protonated and lipophilic, enabling passive diffusion across Gram-positive bacterial membranes.
Once inside the bacterial cytoplasm, where intracellular pH is comparatively higher, hop acids dissociate and release protons, disrupting the proton motive force required for ATP synthesis, nutrient transport, amino acid uptake, and membrane potential maintenance.
This membrane-mediated mechanism fundamentally differs from target-specific antibiotic inhibition and is less susceptible to resistance development through single-gene mutation pathways.
Commercial Performance
Bench-scale evaluations and commercial dry-mill field trials documented effective bacterial suppression relative to conventional antibiotic programs.
In a commercial evaluation conducted at pH 4.5, FermaHop Pro+ maintained ethanol-to-solids conversion efficiency while matching or improving lactic acid suppression, resulting in $51 in savings per batch relative to the incumbent antimicrobial program. Results demonstrated stable antimicrobial performance relative to the incumbent conventional antibiotic program.
DDGS and Regulatory Implications
Because FermaHop Pro+ does not contain conventional antibiotics, DDGS produced from treated fermentations remain free of antibiotic active ingredients associated with medically important antimicrobial classes.
This supports improved feed-market positioning, reduced residue-monitoring requirements, simplified export compliance, and alignment with industry initiatives focused on reducing antibiotic dependence.
Conclusion
FermaHop Pro+ was developed to provide broad-spectrum suppression of Gram-positive bacterial contaminants across the full pH range encountered in commercial dry-mill ethanol fermentation. By disrupting bacterial proton motive force rather than targeting discrete intracellular enzymes or ribosomal targets, the technology delivers stable antimicrobial performance with lower target-specific selective pressure than conventional antibiotic programs.
Commercial evaluations demonstrated maintained ethanol yield performance, controlled lactic acid accumulation, simplified bacterial-control program management, and measurable cost savings while reducing or eliminating antibiotic use.
In many ethanol facilities, increasing lactic acid levels despite increasing antibiotic dosage may indicate the emergence of bacterial populations with increased tolerance or reduced susceptibility to conventional antibiotics. Because hop-acid antimicrobial activity functions by disrupting the cytoplasmic pH gradient of the cell rather than target-specific biochemical inhibition, FermaHop Pro+ provides an alternative bacterial-control strategy capable of maintaining efficacy under conditions where conventional antibiotic performance fails to meet expectations.